ERAS 8-K: Fda approval
Erasca
Filed with the SEC on · accession 0001193125-26-469283
ERAS filed a 8-K (current report) with the SEC on Nov 20, 2026. Erasca announced updated U.S. Phase 1 clinical data for its pan-RAS molecular glue ERAS-0015 showing strong anti-tumor activity across KRAS-mutant solid tumors, and is accelerating a Phase 3 trial in first-line pancreatic cancer to H1 2027.
Summary of the filing
Erasca announced updated U.S. Phase 1 clinical data for its pan-RAS molecular glue ERAS-0015 showing strong anti-tumor activity across KRAS-mutant solid tumors, and is accelerating a Phase 3 trial in first-line pancreatic cancer to H1 2027. The company also reported encouraging initial Phase 1 data for pan-KRAS inhibitor ERAS-4001.
Key details
✦ Ask GOAX AI about this filing — what it means for ERAS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ERAS?
Click hereFrequently asked questions
What did ERAS file with the SEC on Nov 20, 2026?
ERAS filed a 8-K (Fda approval). Erasca announced updated U.S. Phase 1 clinical data for its pan-RAS molecular glue ERAS-0015 showing strong anti-tumor activity across KRAS-mutant solid tumors, and is accelerating a Phase 3 trial in first-line pancreatic cancer to H1 2027. The company also reported encouraging initial Phase 1 data for pan-KRAS inhibitor ERAS-4001.
What does a fda approval mean for ERAS stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other ERAS SEC filings
- SCHEDULE 13G/A · SEC filingNov 16, 2026
- SCHEDULE 13G/A · SEC filingNov 16, 2026
- 10-Q · SEC filingNov 12, 2026
- 8-K · SEC filingNov 12, 2026
- 8-K · Executive departureOct 16, 2026
- 8-K · SEC filingAug 24, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- 8-K · SEC filingAug 11, 2026
- 10-Q · SEC filingAug 11, 2026
- 8-K · Executive departureAug 10, 2026
Get alerts when ERAS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days